🇺🇸 FDA
Pipeline program

EDIT-101

1991-201-008

Phase 2 small_molecule active

Quick answer

EDIT-101 for Leber Congenital Amaurosis 10 is a Phase 2 program (small_molecule) at Editas Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Editas Medicine
Indication
Leber Congenital Amaurosis 10
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials